WallStSmart

Haemonetics Corporation (HAE)vsMedtronic PLC (MDT)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Medtronic PLC generates 2626% more annual revenue ($36.36B vs $1.33B). MDT leads profitability with a 13.2% profit margin vs 7.3%. HAE appears more attractively valued with a PEG of 1.25. MDT earns a higher WallStSmart Score of 62/100 (C+).

HAE

Buy

56

out of 100

Grade: C

Growth: 5.3Profit: 5.5Value: 6.7Quality: 6.0
Piotroski: 4/9Altman Z: 1.63

MDT

Buy

62

out of 100

Grade: C+

Growth: 6.7Profit: 6.5Value: 5.3Quality: 4.8
Piotroski: 2/9
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

HAEUndervalued (+33.9%)

Margin of Safety

+33.9%

Fair Value

$86.95

Current Price

$71.28

$15.67 discount

UndervaluedFair: $86.95Overvalued
MDTUndervalued (+11.4%)

Margin of Safety

+11.4%

Fair Value

$91.83

Current Price

$81.67

$10.16 discount

UndervaluedFair: $91.83Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

HAE1 strengths · Avg: 8.0/10
EPS GrowthGrowth
28.4%8/10

Earnings expanding 28.4% YoY

MDT4 strengths · Avg: 8.3/10
Market CapQuality
$103.20B9/10

Large-cap with strong market position

Price/BookValuation
2.1x8/10

Reasonable price relative to book value

Operating MarginProfitability
21.3%8/10

Strong operational efficiency at 21.3%

Free Cash FlowQuality
$2.08B8/10

Generating 2.1B in free cash flow

Areas to Watch

HAE4 concerns · Avg: 3.8/10
P/E RatioValuation
38.1x4/10

Premium valuation, high expectations priced in

Revenue GrowthGrowth
4.8%4/10

4.8% revenue growth

Altman Z-ScoreHealth
1.634/10

Distress zone — elevated risk

Profit MarginProfitability
7.3%3/10

7.3% margin — thin

MDT2 concerns · Avg: 3.5/10
PEG RatioValuation
1.594/10

Expensive relative to growth rate

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : HAE

The strongest argument for HAE centers on EPS Growth. PEG of 1.25 suggests the stock is reasonably priced for its growth.

Bull Case : MDT

The strongest argument for MDT centers on Market Cap, Price/Book, Operating Margin.

Bear Case : HAE

The primary concerns for HAE are P/E Ratio, Revenue Growth, Altman Z-Score. Debt-to-equity of 1.54 is elevated, increasing financial risk.

Bear Case : MDT

The primary concerns for MDT are PEG Ratio, Piotroski F-Score.

Key Dynamics to Monitor

MDT carries more volatility with a beta of 0.60 — expect wider price swings.

MDT is growing revenue faster at 9.9% — sustainability is the question.

MDT generates stronger free cash flow (2.1B), providing more financial flexibility.

Monitor MEDICAL DEVICES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

MDT scores higher overall (62/100 vs 56/100). HAE offers better value entry with a 33.9% margin of safety. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Haemonetics Corporation

HEALTHCARE · MEDICAL DEVICES · USA

Haemonetics Corporation, a healthcare company, offers medical products and solutions. The company is headquartered in Boston, Massachusetts.

Visit Website →

Medtronic PLC

HEALTHCARE · MEDICAL DEVICES · USA

Medtronic plc is an American-Irish registered medical device company that primarily operates in the United States. Medtronic has an operational and executive headquarters in Fridley, Minnesota in the US.

Want to dig deeper into these stocks?